Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591161 · ClinicalTrials.gov registry record · Phase 3
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
A Phase 3 study of Inflammation and Surgery, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
- 1
- Study location
NCT01591161 is a Phase 3 study of Inflammation and Surgery that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 369 participants, above the 285-participant average among 132 other Inflammation trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01591161, a Phase 3 study of Inflammation and Surgery, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mapracorat
Study Locations (1)
New York
- Bausch & Lomb Incorporated - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591161
The ClinicalTrials.gov registry entry for NCT01591161 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 285-participant average among 132 other Inflammation trials with a reported enrollment target (29% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01591161 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01591161 about?
NCT01591161 is a clinical study titled "Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
What is the current status of trial NCT01591161?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2012-07. Estimated completion is 2013-07.
What conditions does trial NCT01591161 study?
This clinical trial studies the following conditions: Inflammation, Surgery, Cataract.
What interventions are being tested in trial NCT01591161?
The interventions under investigation include: Placebo (DRUG), Mapracorat (DRUG).
Who is sponsoring clinical trial NCT01591161?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01591161 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
COMPLETED · Phase 3
-
A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.